Press Releases

2023 2022 2021 2020 2019 2018 2017 2016 2015

Date	Title	Download
Oct 2 2023	MEI Pharma Adopts Limited-Duration Stockholder Rights Plan	PDF
Sep 28 2023	MEI Pharma Issues Statement Regarding Anson and Cable Car’s Opportunistic Actions	PDF
Sep 26 2023	MEI Pharma Reports Fiscal Year 2023 Results and Operational Highlights	/sites/meipharma-corp/files/2023-09/meip-q4-2023fye-earnings-final.pdf
Sep 21 2023	MEI Pharma to Report 2023 Fiscal Year End Financial Results and Provide Corporate Overview on September 26, 2023	PDF
Sep 18 2023	MEI Pharma Confirms Receipt of Director Nominations From Anson and Cable Car	PDF
Aug 16 2023	MEI Pharma Announces First Patient Dosed in Clinical Study Evaluating ME-344 Plus Bevacizumab (AVASTIN®) in Patients with Previously Treated Metastatic Colorectal Cancer	PDF
Jul 23 2023	MEI Pharma Announces Results of Special Meeting of Stockholders	PDF
Jul 19 2023	MEI Pharma Reminds Shareholders to Vote Today FOR the Infinity Transaction	PDF
Jul 18 2023	MEI Pharma Responds to Anson and Cable Car	PDF
Jul 17 2023	MEI Pharma Encourages Shareholders to Vote FOR the Infinity Transaction	PDF
Jul 13 2023	MEI Pharma Postpones Special Meeting of Shareholders	PDF
Jul 11 2023	MEI Pharma Provides Final Reminder to Shareholders to Vote Today FOR the Merger With Infinity Pharmaceuticals	PDF
Jul 7 2023	MEI Pharma Reminds Shareholders to Vote FOR the Merger with Infinity Pharmaceuticals	PDF
Jul 5 2023	MEI Pharma Highlights Recommendation by Leading Independent Proxy Advisory Firm ISS to Vote “FOR” Pending Transaction with Infinity Pharmaceuticals	PDF
Jun 29 2023	MEI Pharma Mails Letter to Shareholders Reiterating Value Creating Potential of Proposed Transaction with Infinity Pharmaceuticals	PDF
Jun 27 2023	MEI Pharma Responds to Anson and Cable Car	PDF
Jun 15 2023	MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates	PDF
Jun 13 2023	MEI Pharma Announces Planned Departure of Chief Financial Officer Brian Drazba and Appointment of Justin File as Successor	PDF
Jun 2 2023	MEI Pharma Announces Planned Departure of CEO Daniel P. Gold, Ph.D. and Appointment of David M. Urso as Successor	PDF
Jun 1 2023	MEI Pharma Board of Directors Rejects Unsolicited Proposal	PDF
May 30 2023	MEI Pharma Confirms Receipt of Unsolicited Acquisition Proposal	PDF
May 23 2023	MEI Pharma Announces Update of Ongoing Phase 1 Study Evaluating Oral CDK9 Inhibitor Voruciclib Alone and in Combination with Venetoclax in Patients with Acute Myeloid Leukemia or B-Cell Malignancies	PDF
May 11 2023	MEI Pharma Reports Third Quarter Fiscal Year 2023 Results and Operational Highlights	/sites/meipharma-corp/files/2023-05/meip-q3-2023-fiscal-earnings.pdf
Apr 14 2023	MEI Pharma Announces 1-for-20 Reverse Stock Split	PDF
Feb 23 2023	MEI Pharma and Infinity Pharmaceuticals Announce Definitive Merger Agreement to Advance Three Promising Clinical Oncology Candidates	PDF
Feb 9 2023	MEI Pharma Reports Second Quarter Fiscal Year 2023 Results and Operational Highlights	/sites/meipharma-corp/files/2023-02/meip-q2-2023-fiscal-earnings.pdf

Date	Title	Download
Dec 6 2022	MEI Pharma Announces Adjournment of Annual Meeting of Stockholders	PDF
Dec 5 2022	MEI Pharma Initiates Strategic Realignment	PDF
Dec 5 2022	MEI Pharma and Kyowa Kirin Announce Discontinuation of Zandelisib Development Outside of Japan Following Recent FDA Meeting	PDF
Nov 18 2022	Kyowa Kirin and MEI Pharma Announce Topline Data from the Phase 2 MIRAGE Study Evaluating Zandelisib in Patients with Indolent B-cell non-Hodgkin’s Lymphoma in Japan	PDF
Nov 14 2022	MEI Pharma Reports First Quarter Fiscal Year 2023 Results and Operational Highlights	/sites/meipharma-corp/files/2022-11/meip-q1-2023-fiscal-earnings-final.pdf
Nov 3 2022	MEI Pharma and Kyowa Kirin Announce Acceptance of Three Abstracts for Presentation at the American Society of Hematology Annual Meeting 2022	PDF
Oct 3 2022	MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)	PDF
Sep 22 2022	MEI Pharma Announces Changes to Board of Directors	PDF
Sep 8 2022	MEI Pharma Reports Fiscal Year 2022 Results and Operational Highlights	/sites/meipharma-corp/files/2022-09/meip-2022-earnings-release-final.pdf
Sep 6 2022	MEI Pharma to Present at the H.C. Wainwright 24th Annual Global Investment Conference 2022	PDF
Sep 1 2022	MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)	PDF
Sep 1 2022	MEI Pharma to Release 2022 Fiscal Year End Financial Results and Provide Corporate Update on September 8, 2022	PDF
Aug 1 2022	MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)	PDF
Jul 18 2022	MEI Pharma and Kyowa Kirin Announce Publication in The Lancet Oncology of Data from Phase 1b Clinical Study of Zandelisib in Patients with Relapsed or Refractory B-cell Malignancy	PDF
Jul 1 2022	MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)	PDF
Jun 22 2022	MEI Pharma Appoints Human Resources Executive Anne Frese as Chief People Officer	PDF
Jun 10 2022	MEI Pharma and Kyowa Kirin Report Clinical Data on Zandelisib at European Hematology Association 2022 Hybrid Congress	PDF
Jun 4 2022	MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022	PDF
Jun 1 2022	MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	PDF
May 26 2022	MEI Pharma and Kyowa Kirin Announce Acceptance of Abstract for Presentation at the American Society of Clinical Oncology Annual Meeting 2022	PDF
May 23 2022	MEI Pharma Reports Third Quarter Fiscal Year 2022 Results and Operational Highlights	/sites/meipharma-corp/files/meip-q3-2022-fiscal-earnings.pdf
May 17 2022	MEI Pharma to Present at the H.C. Wainwright Global Investment Conference 2022	PDF
May 12 2022	MEI Pharma and Kyowa Kirin Announce Acceptance of Two Abstracts for Presentation at the European Hematology Association 2022 Hybrid Congress	PDF
May 2 2022	MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	PDF
Apr 8 2022	MEI Pharma Announces Two Presentations at the American Association for Cancer Research Annual Meeting 2022	PDF
Apr 1 2022	MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	PDF
Mar 24 2022	MEI Pharma and Kyowa Kirin Provide Regulatory Update on Zandelisib Following Meeting with the FDA	/sites/meipharma-corp/files/2022-03/zandelisib-fda-update-march2022-final.pdf
Mar 8 2022	MEI Pharma Announces Acceptance of Two Abstracts for Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022	PDF
Mar 1 2022	MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)	PDF
Feb 10 2022	MEI Pharma Reports Second Quarter Fiscal Year 2022 Results and Operational Highlights	/sites/meipharma-corp/files/meip-q2-2022-fiscal-earnings.pdf
Feb 7 2022	MEI Pharma Strengthens Clinical and Quality Expertise with New Key Executive Appointments	PDF
Jan 3 2022	MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	PDF

Date	Title	Download
Dec 6 2021	MEI Pharma Announces Closing of Public Offering of Common Stock	PDF
Dec 3 2021	MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	PDF
Dec 1 2021	MEI Pharma Announces Pricing of Public Offering of Common Stock	PDF
Nov 30 2021	MEI Pharma Announces Proposed Public Offering of Common Stock	PDF
Nov 23 2021	MEI Pharma Appoints Biotechnology Executive Sujay Kango to its Board of Directors	PDF
Nov 10 2021	MEI Pharma Reports First Quarter Fiscal Year 2022 Results and Operational Highlights	/sites/meipharma-corp/files/meip-q1-2022-fiscal-earnings.pdf
Nov 10 2021	MEI Pharma and Kyowa Kirin receive Orphan Drug Designation for Zandelisib for the Treatment of Follicular Lymphoma	/sites/meipharma-corp/files/pr-11-10-2021.pdf
Nov 4 2021	MEI Pharma Announces Acceptance of Three Abstracts for Presentation at the 63rd Annual American Society of Hematology Annual Meeting	/sites/meipharma-corp/files/pr-11-04-2021.pdf
Nov 1 2021	MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)	PDF
Oct 1 2021	MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	PDF

Date	Title	Download
Nov 10 2020	MEI Pharma Reports First Quarter Fiscal Year 2021 Results and Operational Highlights	PDF
Nov 9 2020	MEI Pharma to Present at Two Upcoming Investor Healthcare Conferences	PDF
Oct 2 2020	Kyowa Kirin and MEI Pharma Announce First Patient Dosed in Japanese Pivotal Phase 2 Study of Zandelisib in Patients with Indolent B-cell non-Hodgkin's Lymphoma	PDF
Sep 15 2020	MEI Pharma Appoints Brian T. Powl As Senior Vice President, Marketing	PDF
Sep 9 2020	MEI Pharma Reports Fiscal Year 2020 Results and Operational Highlights	PDF
Sep 4 2020	MEI Pharma to Present at Upcoming Investor Conferences in September	PDF
Sep 2 2020	MEI Pharma to Release 2020 Fiscal Year End Financial Results and Provide Corporate Update on September 9, 2020	PDF
Aug 4 2020	MEI Pharma to Present at the BTIG Virtual Biotechnology Conference 2020	PDF
Jul 2 2020	Helsinn Group and MEI Pharma Discontinue the Phase 3 Study with Pracinostat in AML after Completing Interim Analysis	PDF
May 27 2020	MEI Pharma to Present at the Jefferies Virtual Healthcare Conference	PDF

Date	Title	Download
Dec 19 2019	MEI Pharma Announces Closing of Public Offering of Common Stock	PDF
Dec 17 2019	MEI Pharma Announces Pricing of Public Offering of Common Stock	PDF
Dec 16 2019	MEI Pharma Announces Proposed Public Offering of Common Stock	PDF
Nov 12 2019	MEI Pharma to Present at the Stifel 2019 Healthcare Conference	PDF
Nov 7 2019	MEI Pharma Reports First Quarter Fiscal Year 2020 Results and Operational Highlights	PDF
Oct 3 2019	MEI Pharma Announces Updated Clinical Data from ME-401 Phase 1b Study in Patients with Indolent B-cell Malignancies	PDF
Sep 23 2019	MEI Pharma to Host Investor and Analyst Event on October 4, 2019	PDF
Aug 29 2019	MEI Pharma to Present at the 2019 Wells Fargo Healthcare Conference	PDF
Aug 28 2019	MEI Pharma Reports Fiscal Year 2019 Results and Operational Highlights	PDF
Aug 21 2019	MEI Pharma to Release 2019 Fiscal Year End Financial Results and Provide Corporate Update on August 28, 2019	PDF

Date	Title	Download
Dec 3 2018	Phase 2 Interim Data Evaluating the Combination of Pracinostat and Azacitidine in Patients with Myelodysplastic Syndrome Presented at the 2018 American Society of Hematology Annual Meeting	PDF
Dec 2 2018	MEI Pharma Presents Clinical Data from Ongoing Phase 1b Study of ME-401 in Patients with Indolent B-Cell Malignancies at the 2018 American Society of Hematology Annual Meeting	PDF
Dec 1 2018	MEI Pharma Presents Preclinical Data Demonstrating Voruciclib Synergistically Induces Apoptosis in Combination with Venetoclax in Acute Myeloid Leukemia Cells at the 2018 American Society of Hematology Annual Meeting	PDF
Nov 8 2018	MEI Pharma Reports First Quarter Fiscal Year 2019 Results and Operational Highlights	PDF
Nov 6 2018	MEI Pharma To Present at Stifel 2018 Healthcare Conference	PDF
Nov 5 2018	MEI Pharma and Kyowa Hakko Kirin Announce License Agreement to Develop and Commercialize ME-401 in Japan	PDF
Nov 1 2018	MEI Pharma to Present Clinical Data from Three Oncology Programs at the 2018 American Society of Hematology (ASH) Annual Meeting	PDF
Oct 11 2018	MEI Pharma and BeiGene Announce Clinical Collaboration to Evaluate ME-401 in Combination with Zanubrutinib in Patients with B-Cell Malignancies	PDF
Aug 30 2018	MEI Pharma Reports Fiscal Year 2018 Results and Operational Highlights	PDF
Aug 29 2018	MEI Pharma To Present at Wells Fargo Securities 2018 Healthcare Conference	PDF

Date	Title	Download
Dec 21 2017	MEI Pharma Announces Study of Clinical Stage Oral CDK Inhibitor Voruciclib Published in Nature Scientific Reports	PDF
Nov 22 2017	MEI Pharma to Host Annual Meeting of Stockholders	PDF
Nov 8 2017	MEI Pharma Reports First Quarter Fiscal Year 2018 Results	PDF
Nov 7 2017	MEI Pharma to Present at Stifel 2017 Healthcare Conference	PDF
Sep 19 2017	MEI Pharma to Present at Cantor Fitzgerald Global Healthcare Conference	PDF
Sep 5 2017	MEI Pharma Announces Exclusive License Agreement with Presage Biosciences for Voruciclib, An Oral, Selective CDK Inhibitor	PDF
Sep 5 2017	MEI Pharma Reports Fiscal Year 2017 Results	PDF
Aug 31 2017	MEI Pharma to Present at Two Upcoming Investor Conferences	PDF
Aug 29 2017	MEI Pharma to Host Fiscal Year End Conference Call on September 5, 2017	PDF
Aug 2 2017	Helsinn Group and MEI Pharma Announce First Patient Dosed in Pivotal Phase 3 Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia	PDF

Date	Title	Download
Dec 5 2016	Helsinn Group and MEI Pharma Report Prolongation of Survival Results from Phase 2 Clinical Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia	PDF
Nov 17 2016	MEI Pharma to Host Annual Meeting of Stockholders	PDF
Nov 9 2016	MEI Pharma Reports First Quarter Fiscal Year 2017 Results	PDF
Nov 7 2016	MEI Pharma to Present at Stifel Healthcare Conference	PDF
Nov 3 2016	Helsinn Group and MEI Pharma Announce Long-Term Survival and Response Data from Phase II Clinical Study of Pracinostat in Acute Myeloid Leukemia Accepted for Oral Presentation at Upcoming American Society of Hematology Annual Meeting	PDF
Sep 6 2016	MEI Pharma Reports Fiscal Year 2016 Results	PDF
Aug 10 2016	MEI Pharma to Present at Wedbush PacGrow Healthcare Conference	PDF
Aug 8 2016	Helsinn Group and MEI Pharma Enter Strategic Agreement for the Development and Commercialization of Pracinostat for the Treatment of Acute Myeloid Leukemia and Other Hematologic Diseases	PDF
Aug 1 2016	MEI Pharma's Pracinostat Receives Breakthrough Therapy Designation from FDA for Treatment in Combination with Azacitidine of Patients with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Chemotherapy	PDF
Apr 20 2016	MEI Pharma Announces New Clinical Data from First-in-Human Study of ME-401, A Next Generation Oral PI3K Delta Inhibitor	PDF

Date	Title	Download
Dec 10 2015	MEI Pharma Appoints Dr. Christine White as Chairman of the Board	PDF
Dec 7 2015	MEI Pharma Announces Positive Results from Phase II Study of Pracinostat in Acute Myeloid Leukemia, Plans to Initiate Phase III Registration Study	PDF
Nov 23 2015	MEI Pharma to Host Annual Meeting of Stockholders	PDF
Nov 11 2015	MEI Pharma to Present at Stifel Healthcare Conference	PDF
Nov 5 2015	MEI Pharma Highlights New Data from Phase II Clinical Studies of Pracinostat in Acute Myeloid Leukemia and Myelodysplastic Syndrome	PDF
Oct 19 2015	MEI Pharma to Present at 14th Annual BIO Investor Forum	PDF
Oct 6 2015	MEI Pharma Announces Data from Phase II Clinical Studies of Pracinostat Accepted for Oral Presentation at American Society of Hematology Annual Meeting	PDF
Sep 2 2015	MEI Pharma Reports Fiscal Year 2015 Results	PDF
Aug 4 2015	MEI Pharma to Present at Wedbush PacGrow Healthcare Conference	PDF
Jul 1 2015	MEI Pharma to Present at Cantor Fitzgerald Healthcare Conference	PDF